Iowa House sends bill regulating pharmacy benefit managers to Gov. Kim Reynolds
- The Iowa House approved Senate File 383 on May 12, 2025, sending a bill regulating pharmacy benefit managers to Governor Kim Reynolds in Des Moines.
- The bill aims to curb pharmacy benefit managers' practices that contribute to the closure of over 200 Iowa pharmacies and rising drug prices nationwide.
- It requires pharmacies to be reimbursed at or above average state or national drug acquisition costs plus a $10.68 dispensing fee, with new restrictions on PBM strategies favoring certain pharmacies.
- The legislation passed 75-15, with supporters citing protection for rural pharmacies and opponents warning it could increase insurance costs by about $169 per insured Iowan annually and add $340 million to private plans.
- If signed into law, Iowa will join other states enacting PBM reforms intended to improve pricing transparency and preserve local pharmacies, although concerns about increased costs remain.
28 Articles
28 Articles
Sen. Britt challenges current pharmacy benefit structure
U.S. Sen. Katie Britt, R-Alabama, attended a Senate Judiciary Committee hearing entitled “PBM Power Play: Examining Competition Issues in the Prescription Drug Supply Chain” to examine the role of pharmacy benefit managers. She heard from a number of witnesses, including Dr. Randy McDonough, cofounder and owner of Towncrest Pharmacy; Dr. Neeraj Sood, a professor at the University of Southern California’s Price School of Public Policy; and Dr. Sh…


Stopping a ‘moral obscenity’: Senate Judiciary Committee expresses support for PBM reform
Sen. Chuck Grassley, R-Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass President Donald Trump’s conservative megabill this summer.


Prescription drug pricing bill heads to Iowa governor’s desk
The Iowa House approved a bill Monday that would place limits on pharmacy benefit managers, which function as intermediaries between insurance providers and drug manufacturers.
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage